HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Related articles in The JI Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wherry, E. J. Articles by Eisenlohr, L. C. Search for Related Content PubMed PubMed Citation Articles by Wherry, E. J. Articles by Eisenlohr, L. C. Pubmed/NCBI databases Substance via MeSH

Re-evaluating the Generation of a "Proteasome-Independent" MHC Class I-Restricted CD8 T Cell Epitope¹

Department of Microbiology and Immunology, Jefferson Medical College and Kimmel Cancer Institute, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, 19107

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The proteasome is primarily responsible for the generation of MHC class I-restricted CTL epitopes. However, some epitopes, such as NP_147–155 of the influenza nucleoprotein (NP), are presented efficiently in the presence of proteasome inhibitors. The pathways used to generate such apparently "proteasome-independent" epitopes remain poorly defined. We have examined the generation of NP_147–155 and a second proteasome-dependent NP epitope, NP_50–57, using cells adapted to growth in the presence of proteasome inhibitors and also through protease overexpression. We observed that: 1) Ag processing and presentation proceeds in proteasome-inhibitor adapted cells but may become more dependent, at least in part, on nonproteasomal protease(s), 2) tripeptidyl peptidase II does not substitute for the proteasome in the generation of NP_147–155, 3) overexpression of leucine aminopeptidase, thymet oligopeptidase, puromycin-sensitive aminopeptidase, and bleomycin hydrolase, has little impact on the processing and presentation of NP_50–57 or NP_147–155, and 4) proteasome-inhibitor treatment altered the specificity of substrate cleavage by the proteasome using cell-free digests favoring NP_147–155 epitope preservation. Based on these results, we propose a central role for the proteasome in epitope generation even in the presence of proteasome inhibitors, although such inhibitors will likely alter cleavage patterns and may increase the dependence of the processing pathway on postproteasomal enzymes.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The CD8⁺ T cell recognition of antigenic peptides displayed by major histocompatibility class I molecules at the cell surface requires the precise proteolytic extraction of epitopes from their native protein contexts (1, 2, 3). In most cases, a cytosolic phase is required in the generation of 8–11 aa fragments that are ultimately expressed at the cell surface. After transport into the endoplasmic reticulum (ER)⁴ by the transporter associated with Ag presentation (TAP), peptides conforming to allele-specific binding constraints stabilize the MHC class I (MHC I)/₂-microglobulin complex allowing egress to the cell surface for T cell stimulation (1, 2, 3). The specificity and efficiency with which peptides are generated in the cytosol strongly influences the subsequent CTL response.

Several important experimental observations support a central role for the proteasome in the cytosolic phase of MHC I-restricted Ag processing. First, protease inhibitors that block at least some functions of the proteasome inhibit the presentation of numerous epitopes and can hinder the proper maturation of many MHC I alleles, presumably due to the consequent paucity of peptides in the ER (2). Second, the expression of several proteasome components, including catalytically active subunits (LMP2, LMP7, and LMP10) and a potential activator complex (PA28), can be up-regulated in response to IFN- and are incorporated into the proteasome. The resulting "immunoproteasomes" favor the generation of peptides suited for presentation by MHC I molecules (2). Third, it has been possible in some cases to demonstrate precise epitope generation in cell-free digests using purified proteasome and synthetic epitope precursors (2). Finally, the posthydrophobic cleavage activity of the proteasome (the chymotryptic-like activity) is considered to be critical for generating the hydrophobic C-termini of peptides that is preferred by murine TAP and many human and murine class I alleles (1). This correlation between proteasome cleavage and TAP and MHC preference suggests a coevolution of the degradation and presentation components of the class I processing pathway (1). Notably, posthydrophobic cleavage is the rate-limiting activity for protein degradation and is the activity most potently blocked by proteasome inhibitors (4). Following initial proteasomal cleavage, additional trimming events may be required to generate precise MHC class I-binding peptides (5, 6). This trimming may occur in the cytosol (7, 8, 9) or ER (6, 10, 11, 12, 13) and may occur more efficiently at the N terminus of epitope precursors than at the C terminus, further supporting the notion that the proteasome plays a central role in generating the C terminus of epitopes during initial processing.

Despite the abundant evidence implicating the proteasome in Ag processing, its obligatory role in some cases is unclear. We have demonstrated previously that N-Ac-Leu-Leu-norleucinal (LLnL) and lactacystin (Lac), two potent inhibitors of the proteasome, fail to block, and actually enhance, presentation of the H-2K^d-restricted epitope from influenza A PR/8/34 nucleoprotein (NP), NP_147–155 (14, 15). Furthermore, mutation of an immediately flanking alanine residue to a proline (influenza NP with aa 146 mutated from alanine to proline (A146P)) results in a substrate that can be processed to yield the antigenic peptide only in the presence of these inhibitors (14). Subsequent reports described a similar presentation phenotype for several other epitopes (16, 17, 18, 19, 20, 21, 22). In addition, cell-free proteasome digests do not always result in the generation of epitopes produced in, and presented by, intact cells (14, 23, 24), suggesting that other proteases may be involved in the generation of some epitopes. NP_147–155 is destroyed rather than generated by the proteasome during such digests (14, 23), a result that is greatly accentuated by the A146P mutation (14). Therefore, NP_147–155 production may involve the action of proteases operating in parallel with the proteasome that are effective only in the absence of fully functional proteasome (which could serve to destroy the epitope). Alternatively, production may involve a combination of both proteasomal and nonproteasomal activities.

A proteolytic activity that can compensate for reduced proteasome function has been identified (25, 26). The activity of a high m.w. complex, larger than, and distinct from, the proteasome is increased in cells adapted to grow in the presence of irreversible inhibitors of the proteasome (25, 26). In Lac-adapted EL-4 cells, this enzyme has been identified as tripeptidyl peptidase II (TPP II) (26). This large cytosolic protease was originally described as a high m.w. oligomeric, extralysosomal aminopeptidase purified from rat liver homogenates (27, 28). TPP II is an efficient tripeptide aminopeptidase and has been demonstrated to generate peptides ranging from 7 to 27 aa from a 41 aa substrate through both exo- and endoproteolytic activity, implying that it may function to generate peptides for MHC I-restricted presentation (26). In support of this possibility, EL-4 cells adapted to grow in the presence of the irreversible inhibitor of the proteasome carbobenzoxy-Leu-Leu-Leu-vinyl sulfone (Z-L₃-VS) continue to express stable, mature, MHC I molecules, suggesting the availability of peptides in the ER despite a chronic deficiency in proteasome activity (25, 29). However, the capacity of cells with chronically impaired proteasomes to present specific peptides to CD8 T cells has not been completely addressed, and the contribution of up-regulated protease activities, including TPP II, to Ag processing under these conditions requires additional investigation. TPP II has been proposed to perform proteasome-independent processing (30) or proteasome-dependent trimming (31, 32). Therefore, TPP II could account for the first steps in epitope generation under conditions of proteasome inhibition, or, alternatively, TPP II and/or additional proteases may trim proteasomal products to liberate precise epitopes and this activity may be more important when proteasome function is suboptimal. It is currently unclear whether the Ag processing role of TPP II can account for the generation of epitopes refractory to proteasome inhibitors. In addition to TPP II, several reports have demonstrated that other nonproteasomal cytosolic proteases may contribute to the generation or destruction of antigenic peptides via post proteasomal trimming. These include LA (33), thymet oligopeptidase (TO) (34, 35), bleomycin hydrolase (BH), and puromycin-sensitive aminopeptidase (PSA) (32, 36). In addition to these cytosolic proteases, ER-resident amino peptidase (ERAAP or ERAP1 in the mouse, ERAP1/2 complex in the human) can further trim peptides at the N terminus once they have been transported via TAP (10, 11, 12, 13).

In the present study, we investigated the role of the proteasome and nonproteasomal cytosolic proteases in the generation of two NP epitopes: NP_50–57, ordinarily dependent on proteasome function, and NP_147–155, enhanced in the presence of proteasome inhibitors. Our results do not support the existence of a "proteasome-independent" pathway for the production of epitopes such as NP_147–155. Rather, our data favor a model in which NP_147–155 generation depends on proteasome activities that persist in the presence of proteasome inhibitors along with the action of additional Ala-Ala-Phe-chloromethyl ketone (AAF-cmk)-sensitive postproteasomal proteases.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Cells, viruses, and inhibitors

L929 cells transfected with the K^d gene (L-K^d) and B8 fibroblasts were maintained in DMEM with 5% FCS. L-K^d and B8 murine fibroblasts were adapted to grow in the presence of increasing concentrations of the irreversible proteasome inhibitor Z-L₃-VS as described previously (25). Adapted cells were maintained in 10 µM Z-L₃-VS, and adaptation was confirmed by the ability to grow in the presence of 50 µM Z-L₃-VS and altered cleavage of fluorogenic substrates (see below). P815 cells adapted to grown in serum-free medium were maintained in OPTI-MEM (Invitrogen Life Technologies) without any serum supplement. Vaccinia virus (vac) encoding NP, NP_50–57, NP_147–155, NP (A146P), OVA, and all hairpin (HP) NP constructs have been described previously (14, 37). Vac expressing TPP II was generated by excising the cDNA encoding murine TPP II from pCDNA3 (provided by Dr. B. Tomkinson, University of Uppsala, Uppsala, Sweden, through S. Renn and Dr. P. Taghert, Washingtion University School of Medicine, St. Louis, MO) with EcoRI and NotI, ligating into EcoRI/NotI cut pBluescript (Stratagene), excising from pBluescript with SalI/NotI, and cloning into the SalI/NotI sites of the plasmid pSC11. Recombinant vac was generated as described previously (38). The irreversible proteasome inhibitor Z-L₃-VS (39) was a gift from Drs. M. Bogyo (University of San Francisco, San Francisco, CA) and H. Ploegh (Harvard University, Boston MA). Lac was purchased from E. J. Correy (Harvard University, Boston MA). LLnL (calpain inhibitor I) was purchased from Calbiochem. Butabindide was purchased from Tocris Bioscience, and AAF-cmk and other chemicals were purchased from Sigma-Aldrich. All inhibitors were used as a 1000x stock in DMSO unless otherwise noted. All restriction endonucleases were purchased from New England Biolabs.

Enzyme assays

Purified bovine 20S proteasome, used in initial experiments, was a gift from Dr. G. DeMartino (University of Texas Southwestern Medical Center, Dallas, TX), and purified drosophila TPP II was a gift from S. Renn and Dr. P. Taghert. 20S proteasome used for all reported experiments was later acquired from Boston Biochim. The fluorogenic peptide substrates N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (suc-LLVY-AMC), N-cbz-Leu-Leu-Glu--naphthylamide (LLE-NA), and Ala-Ala-Phe-7-amido-4-methylcoumarin (AAF-AMC) were purchased from Sigma-Aldrich and used at final concentrations of 100, 100, and 50 µM, respectively, unless otherwise noted. Cell extracts were prepared by lysing 10⁶ cells in 50 µl of 50 mM Tris (pH 7.4) with 1% Triton X-100 on ice for 10 min. The lysate was spun for 10 min at 12,000 x g, and the supernatant was diluted 10-fold in 100 mM potassium phosphate, 1 mM DTT, and 30% glycerol. Total cell extract (20 µg) was used for assessment of enzyme activity (unless otherwise noted). Purified enzymes (60 ng of proteasome or 150 ng of TPP II) or cell extracts were incubated in protease assay buffer (50 mM Tris (pH 7.8), 1.06 mM EGTA, 2 mM MgCl₂, 0.5 mM 2 ME, and 100 µM bestatin) with the indicated substrates and inhibitors for 1–1.5 h. The reaction was stopped by the addition of 2.5 M HCl (4 µl/100-µl reaction) or quenched with ice-cold ethanol and read on a PerkinElmer LS 50 Luminescence Spectrometer or a Wallac Victor² plate reading fluorometer at an excitation of 360 nm and emission of 460 nm. A bandwidth of 40 nm allowed detection of cleavage of N-cbz-Leu-Leu-Glu--naphthylamide despite the optimal excitation/emission of 335 nm/410 nm.

RNA interference (RNAi)

Three RNAi duplexes, a control RNAi duplex (GCGCGCUUUGUAGGAUUCGdTdT) and two TPP II specific RNAi duplexes directed to two target regions on mouse TPP II gene (TPP II no. 1 RNAi: GAGCCUGAACGGAAUGGAGdTdT and TPP II no. 2 RNAi: CACCUAGUUGUCCACUCCUdTdT), were synthesized by Dharmacon. L-K^d cells were plated in 24-well plates overnight and transfected at 70–80% confluency with 200 nM RNAi duplexes in Oligofectamine reagent (Invitrogen Life Technologies) overnight. Transfection mix was then removed and DMEM with 5% FCS was added. Cells were trypsinized after 48 h and used in enzyme activity and CTL assays.

CTL assays

CTL assays were performed essentially as described previously (14). Briefly, epitope-specific CTL were generated by priming mice with minigene vacs encoded either the NP_50–57 or NP_147–155 epitopes. After at least 2 wk, spleens were removed, homogenized, and restimulated with influenza A PR/8/34 for 6–7 days. Epitope presentation was assessed by infecting target cells with the indicated vac recombinants for 4 h, labeling with 100 µCi ⁵¹Cr/10⁶ cells for 1 h, washing with cold PBS, and coincubating the infected targets with dilutions of epitope-specific CTL populations for an additional 4 h. One-half of the supernatant was harvested, and ⁵¹Cr release was measured by a gamma counter. In assays using inhibitors, brefeldin A (BFA) (Sigma-Aldrich) was added just before coincubation with CTL to a final concentration of 5 µg/ml to alleviate the need to include protease inhibitors when T cells were present. For some assays, cells were pretreated overnight with the protease inhibitor AAF-cmk, washed twice in buffered salt solution/BSA (BSS/BSA), and CTL assays were performed as above in the absence of inhibitors. In experiments involving butabindide, P815 cells adapted to grow in serum-free OPTI-MEM were treated overnight with the inhibitor at 100 µM. Cells were supplemented with fresh butabindide every step till the addition of in vitro-stimulated splenocytes.

Gel filtration

A total of 4 x 10⁷ L-K^d cells was treated for 12 h with 50 µM AAF-cmk, washed twice with BSS/BSA, and infected with 3 pfu/cell of either control vac or TPP II expressing vac in the absence of inhibitors. After 9.5 h, cells were lysed in 200 µl of 50 mM Tris plus 1% Triton X-100 (pH 7.4) on ice for 10 min. The lysate was centrifuged at 12,000 x g for 10 min, and the supernatant was loaded directly onto a Superose 6 column (Pharmacia). The column was eluted at a flow rate of 0.2 ml/min, and 2-min (0.4 ml) fractions were collected into chilled tubes containing 100 µl each 5x protease storage buffer (500 mM KPO₄, 5 mM DTT, and 75% glycerol). Each fraction was assayed for cleavage of fluorogenic substrates as above.

Peptide digestion with purified proteasome

Short-term digestion. Five micrograms of purified 20S proteasome (Boston Biochem) with or without 20 µM Lac was incubated in reaction buffer containing 50 mM HEPES (pH 7.6), 0.5 mM EDTA, 2.0 mM MgCl₂, 1.0 mM DTT, and 0.03% SDS for 30 min at 37°C. Fifty micrograms of the NLNDATYQRTRALVRTGMD peptide was added, and the samples were again incubated for 2 h at 37°C.

Long-term digestion. The procedure was similar to the short-term digestion, except 40 µg of the NLNDATYQRTRALVRTGMD peptide was incubated with 5 µg of purified 20S proteasome with or without 20 µM Lac in 50 mM HEPES (pH 7.6), 0.5 mM EDTA, and 0.03% SDS for 24 h at 37°C. In both cases, proteasomes were then removed by filtering the reaction sample through a Centriplus YM-10 unit (Millipore) at 4°C. SDS was removed from the sample as described previously (40). The digests were separated by reverse phase HPLC on a Vydac C18 column. Eluent A contained 0.1% trifluoroacetic acid, eluent B, and 0.1% trifluoroacetic acid in 99.9% acetonitrile. Elution was performed at a 1.0 ml/min flow rate in the linear gradient of eluent B (0–60%) over 40 min. Peak fractions were collected, vacuum-dried, and analyzed by surface-enhanced laser desorption ionization mass spectrometry.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Proteasome inhibitor sensitivity of NP epitopes

We have observed previously that two MHC I-restricted epitopes of influenza A PR/8/34 NP exhibit opposite sensitivities to protease inhibitors that affect the proteasome (14, 15). Processing and presentation of NP_50–57 to CTL is diminished in the presence of the proteasome inhibitor Lac (Fig. 1A), especially when Ag expression is limited (15). In contrast, generation of NP_147–155 from a full-length Ag is increased under similar conditions (Fig. 1A and Ref.15). Presentation of NP_50–57 and NP_147–155 epitopes from minigene constructs that do not require processing is unaffected by proteasome inhibitors (Fig. 1B). In addition, mutation of NP residue 146 (just preceding the NP_147–155 epitope) from an alanine to a proline (A146P) abrogates presentation of NP_147–155 (14). NP_147–155 presentation from this A146P mutant is completely restored in the presence of proteasome inhibitors, including Lac, LLnL, and Z-L₃-VS (Fig. 1C and Ref.14). This provides a useful model Ag to investigate the role of different proteases in the processing of the apparently proteasome-independent NP_147–155 epitope. Interestingly, a similar alanine to proline mutation in the flanking region of an HIV gag epitope also impairs processing (41). The unusual, but not unique (16, 17, 18, 19, 20, 21, 22), presentation phenotype of NP_147–155 suggests that there may be proteasome-independent Ag processing pathways that favor the generation of epitopes like NP_147–155.

View larger version (28K): [in this window] [in a new window]   FIGURE 1. The effect of inhibitors of the proteasome on presentation of NP50–57 and NP147–155. A, Presentation of NP50–57 and NP147–155 in L-Kd cells from full-length NP expressed by vac was assessed in a standard 51Cr release assay in the absence (•) or presence () of Lac (10 µM). Similar results were observed using LLnL (50 µM) and ZL3VS (50 µM; data not shown). B, Presentation of NP50–57 and NP147–155 from vac minigene expression constructs was unaffected by Lac (10 µM). Similar results were observed using LLnL (50 µM) and ZL3VS (50 µM; data not shown). C, Presentation of NP147–155 from the A146P mutated full-length NP was assessed by 51Cr release assay in the absence (•) or presence () of the indicated proteasome inhibitors at the concentrations indicated in A and B. Control vac indicates a recombinant vac expressing an irrelevant Ag.

As a first step in investigating the possibility that proteasome-independent Ag processing pathways exist for the production of NP_147–155, cell lines were adapted to grow in the presence of proteasome inhibitors. Similar proteasome-inhibitor adapted cells have been previously demonstrated to exhibit a dramatic reduction in proteasome activity and a compensatory increase in TPP II activity (25, 26). Despite several observations that suggest peptides are available for MHC I folding in adapted cells and that up-regulated TPP II can prevent the accumulation of ubiquitinylated proteins, the processing and presentation of specific epitopes in proteasome-inhibitor adapted cells has not been fully examined. In addition, although TPP II can trim protein fragments under cell-free conditions to generate antigenic peptides (26, 32), the precise Ag processing role of this protease in intact cells remains unclear. L-K^d cells were adapted to grow in the presence of the irreversible inhibitor Z-L₃-VS essentially as described by Glas et al. (25). A low concentration of Z-L₃-VS (1–10 µM) was toxic to most cells, but by 2–3 wk of culture, a small population of resistant cells emerged. Adapted L-K^d cells were unaffected by higher concentrations of Z-L₃-VS (50 µM) while normal cells died within 2–3 days. In contrast, AAF-cmk, a potent inhibitor of TPP II, killed adapted L-K^d cells in 24–48 h, as observed for adapted EL-4 cells (25), while having no impact on the viability of control L-K^d cells (data not shown).

To assess protease function in the adapted L-K^d cells, the hydrolysis of fluorogenic peptide substrates of the chymotryptic-like activity of the proteasome, suc-LLVY-AMC, or of TPP II activity, AAF-AMC, was measured in cell extracts. As shown in Fig. 2, adapted L-K^d cells had a 90% reduction in suc-LLVY-AMC hydrolyzing activity compared with control cells. As expected, the adapted cells demonstrated a significant increase in a TPP II-like activity as assessed by the hydrolysis of AAF-AMC (Fig. 2B). Similar results were also observed for B8 murine fibroblasts adapted in the same manner (data not shown). Substantially lower, but detectable, AAF-AMC hydrolyzing activity was also detected consistently in nonadapted cells (Fig. 2B). The AAF-AMC hydrolyzing activity detected in both normal and adapted cells was also sensitive to inhibition by AAF-cmk (see Table I), as well as the TPP II peptide inhibitor Arg-Ala-Ser-Val-Ala (28, 42), but not a control peptide (95 vs 0.5% inhibition, respectively). These observations are consistent with a dramatic increase in TPP II activity in Z-L₃-VS-adapted cells.

View larger version (17K): [in this window] [in a new window]   FIGURE 2. Protease activity in Z-L3-VS-adapted cells. Cell extracts from normal L-Kd cells () and L-Kd cells adapted to grow in the presence of Z-L3-VS () were tested for enzyme activity using the fluorogenic peptide substrates suc-LLVY-AMC (substrate for the chymotryptic-like activity of the proteasome) or AAF-AMC (substrate for TPP II). Twenty micrograms of total cellular protein was incubated with 100 µM suc-LLVY-AMC (A) or 50 µM AAF-AMC (B) at 37°C in assay buffer as described in Materials and Methods. The fold increase in AAF-AMC hydrolyzing activity detected in adapted cell extracts in independent experiments was 1.25, 1.4, 1.5, 4.05, 4.5, 7.06 (shown), and 9 similar to other reports of TPP II activity. Similar results were observed for adapted B8 cells (data not shown). The fluorescence in B without substrate (not visible on graph) was 1.032 for normal cells and 1.433 for adapted cells. Greater than 90% reduction in proteasome tryptic-like activity (GGR-AMC hydrolysis) was also observed in extracts from adapted cells (data not shown). Inhibition of the caspase-like activity of the proteasome (LLE-NA hydrolysis) was also observed in adapted cell extracts but at a lower level (30% inhibition); however, purified TPP II also cleaved this substrate (data not shown).

We next asked whether proteasome-inhibitor adapted cells were able to process and present the NP_50–57 and NP_147–155 epitopes from full-length NP. Surprisingly, despite the drastic reduction in proteasome activity, NP_50–57 was efficiently presented by adapted cells (Fig. 3A). Because differences in presentation efficiency may be obscured by Ag overexpression (15), we conducted the same assay using a panel of vac recombinants designed to limit Ag expression in a regulated fashion. By inserting nucleotides predicted to form a thermostable duplex structure, or HP, between the promoter and start codon of the NP gene, the level of protein expression can be modulated and correlates inversely with the number of bases in the HP (15, 37, 43, 44, 45). By using recombinant viruses with 14, 17, and 19 bp HP it was apparent that the presentation of NP_50–57 could proceed in adapted cells and was only mildly compromised compared with normal cells (Fig. 3A). This is in contrast to the effect of short-term proteasome inhibition on the presentation of this epitope (Fig. 1 and Ref.15). As outlined above, acute proteasome inhibitor treatment is beneficial, rather than detrimental, to the generation of NP_147–155. In adapted cells, processing and presentation of NP_147–155 was also enhanced even under conditions of limited Ag expression (Fig. 3B). Furthermore, presentation of NP_147–155 from the proline mutant A146P occurred efficiently in the adapted cells (Fig. 3C) but was completely absent in normal cells. Additional epitopes that are sensitive to proteasome inhibitors (NP_366–374 and OVA_257–264; Refs.14, 15, 46) also continued to be presented in adapted cells at only mildly reduced levels compared with control cells (Fig. 3D and data not shown). In all cases, the presentation of epitopes from minigene expression constructs that do not require processing was essentially the same in adapted cells and normal cells (Fig. 3, A and B, and data not shown). Thus, despite the dramatic reduction in proteasome activity, Z-L₃-VS-adapted cells continued to process Ag and present epitopes to CTL. The efficiency of presentation was nearly normal for the proteasome-dependent NP_50–57 and increased for NP_147–155.

View larger version (38K): [in this window] [in a new window]   FIGURE 3. Epitope presentation in adapted cells. A and B, Normal (•) and Z-L3-VS-adapted () L-Kd cells were infected with vac expressing the indicated constructs and tested for the ability to present NP50–57 (A) or NP147–155 (B) to CTL in a standard 51Cr release assay. To limit Ag expression, constructs containing thermostable duplex barriers or HP between the promoter and initiation codon of the NP gene were used. The size of the HP is indicated. Larger HP result in lower levels of Ag expression. C, Presentation of NP147–155 from the A146P NP construct in normal or Z-L3-VS-adapted L-Kd cells. Similar results were observed in adapted B8 cells (data not shown). Similar results were also obtained with and without inclusion of Z-L3-VS during the course of the CTL assay for adapted cells (data not shown).

The large cytosolic protease TPP II can substitute for some functions of the proteasome when proteasome activity is impaired (25, 26, 29). Because the processing and presentation of NP_147–155 was more efficient in the presence of proteasome inhibitors, we next examined the potential involvement of TPP II in epitope production. As a first step, we investigated protease inhibitors that block the activity of either TPP II or the proteasome. The chloromethyl ketone, AAF-cmk, is a potent inhibitor of TPP II (26). As expected, this compound inhibited purified TPP II, abrogating 100% of the detectable enzyme activity (Table I). Lac at higher concentrations (50 µM) also inhibited TPP II activity (40%) (26), but at 10 µM (the concentration used in this study), no change in TPP II activity was detected (Table I). We observed no change in the chymotryptic-like or caspase-like activity of purified proteasome in the presence of AAF-cmk while Lac or Z-L₃-VS completely blocked the chymotryptic-like activity (Table I; data not shown). Z-L₃-VS also inhibited 35% of the caspase-like activity of purified proteasome (Table I). This inhibition profile was also observed in cell lysates (Table I) where Z-L₃-VS inhibited only activities consistent with the proteasome while AAF-cmk decreased the TPP II-like activity 70% (Table I). The efficient inhibition of purified TPP II by AAF-cmk suggests that the residual (30%) AAF-AMC hydrolysis observed in cell lysates may be due to other protease activities. No significant cleavage of a substrate for the tryptic-like activity of the proteasome (cbz-GGR-bNA) was detected using two different sources of purified proteasome. Cleavage of this substrate was observed in cell lysates, but this activity was not blocked by either Z-L₃-VS or AAF-cmk. Importantly, the specificity of inhibition observed using purified proteases and cell lysates was also maintained in intact cells as treatment with AAF-cmk did not significantly affect proteasome activity while nearly completely eliminating AAF-AMC hydrolyzing activity (data not shown and see below). These data demonstrate that AAF-cmk potently inhibits TPP II without affecting the proteasome, while Lac and Z-L₃-VS preferentially block the chymotryptic-like activity of the proteasome.

Impact of AAF-cmk on epitope presentation

To examine the impact of a TPP II-like activity on the processing and presentation of NP_50–57 and NP_147–155, AAF-cmk was included during CTL assays using both normal and proteasome-inhibitor adapted cells. In nonadapted cells, AAF-cmk inhibits processing and presentation of NP_147–155 but not NP_50–57 from vac-expressed NP (Fig. 4A). This is significant because AAF-cmk represents the first protease inhibitor we have tested that decreases processing and presentation of NP_147–155. For both epitopes, presentation from minigene constructs was unaffected by AAF-cmk. Minigene expression can lead to high epitope levels that mask more subtle effects on Ag presentation. However, lack of AAF-cmk impact on NP_50–57 presentation by untreated cells argues against nonspecific inhibitory effects of this compound. Importantly, in Z-L₃-VS-adapted cells, AAF-cmk inhibited presentation of NP_147–155. We also observed a moderate but consistent (four of four experiments) inhibition of NP_50–57 presentation (Fig. 4B), in contrast to results with nonadapted cells. Presentation of each epitope from a minigene construct was also not substantially affected by AAF-cmk in the adapted cells (Fig. 4, A and B). These results suggest that an AAF-cmk-sensitive proteolytic activity can contribute to the processing of NP_147–155 in normal cells and NP_147–155 and other epitopes in proteasome inhibitor adapted cells. TPP II is an obvious candidate for this processing activity given its role in compensating for chronic proteasome inhibition (25, 26, 29) and studies reporting a trimming (31, 32) or proteasome-independent (30) processing role for this enzyme. However, AAF-cmk may affect other proteases and despite the potent inhibition of TPP II activity by AAF-cmk, epitope presentation was blocked by only 10–50% in adapted cells. Therefore, we developed alternate approaches to examine the role of TPP II in Ag processing more directly.

View larger version (30K): [in this window] [in a new window]   FIGURE 4. Inhibition of epitope presentation by AAF-cmk. A, L-Kd cells were infected with vac expressing minigenes or full-length NP and tested for the ability to process and present NP50–57 or NP147–155 to specific CTL in the absence (•) or presence () of 100 µM AAF-cmk. B, ZL3VS-adapted L-Kd cells were tested as in A for the ability to process and present NP50–57 and NP147–155 from full-length NP (or minigenes) in a standard 51Cr release assay in the absence (•) or presence () of 100 µM AAF-cmk. Additional protease inhibitors, including E64, pepstatin A, bestatin, chymostatin, and diprotin A, also had no effect on the presentation of NP147–155 (data not shown). Closed and open squares indicate recognition of target cells infected with control vac in the absence or presence of 100 µM AAF-cmk. Similar results were also obtained with and without inclusion of Z-L3-VS during the course of the CTL assay for adapted cells (data not shown).

RNAi duplexes were designed to limit TPP II expression and then tested for their ability to inhibit TPP II-like AAF-AMC hydrolysis in cell extracts. This approach, in contrast to the inhibitors used above, represents a highly specific method to reduce TPP II activity. As shown in Fig. 5A, two RNAi duplexes (TPP II no. 1 and TPP II no. 2) targeting different regions of the TPP II mRNA resulted in 50% reduction in AAF-AMC cleavage compared with a control RNAi duplex. At least some of the residual AAF-AMC cleavage activity likely derives from other proteases capable of cleaving this substrate. No reduction, and perhaps a slight increase, in proteasome-like activity was detected following TPP II RNAi transfection (Fig. 5B). Despite this inhibition of TPP II activity using RNAi, NP_147–155 processing and presentation was not significantly changed (Fig. 5C). These data call into question the role of TPP II in the processing of NP_147–155.

View larger version (23K): [in this window] [in a new window]   FIGURE 5. TPP II RNAi. A and B, RNAi constructs were designed targeting two regions of TPP II mRNA. Forty-eight hours after transfection of L-Kd cells with a control RNAi, or each TPP II RNAi individually or together, AAF-AMC (A) and LLE-NA (B) activity was assessed in cell lysates as described in Materials and Methods. Similar results to LLE-NA were observed for LLVY-AMC. C, L-Kd cells transfected with the TPP II RNAi constructs were tested in a 51Cr release assay for presentation of NP147–155 from vac-expressed NP13–498. No change in killing of cells infected with a control vac lacking NP or minigene-expressing vac was observed in cells expressing TPP II RNAi constructs compared with nontransfected or control RNAi transfected cells (data not shown). Similar experiments using control, reporter, constructs routinely achieve 50–60% of the cells transfected (data not shown).

We next evaluated the impact of butabindide, a specific TPP II inhibitor. Because butabindide has been shown to be inactivated by serum factors (31), we used P815 cells that are adapted to grow in serum-free medium. As shown in Fig. 6A, treatment of P815 cells with butabindide did not have any impact on the presentation of NP_147–155. To determine whether butabindide-treated cells indeed have reduced TPP II activity, we performed TPP II (AAF-AMC hydrolyzing) as well as proteasome (bNA hydrolyzing) activity assays using extracts obtained from a portion of butabindide-treated cells. Results show that this activity is reduced remarkably, while proteasome activity is in fact slightly enhanced in butabindide-treated cells (Fig. 6, B and C). Although siRNA exclusively targets TPP II, butabindide may affect other proteases, a potential explanation for the persisting AAF-AMC-cleaving activity with siRNA treatment. Butabindide has, in fact, been demonstrated to inhibit the lysosomally located TPP I (47). In any event, it is clearly very effective at inhibiting TPP II (and any other AAF-AMC hydrolyzing activity) but has no impact on NP_147–155 presentation.

View larger version (16K): [in this window] [in a new window]   FIGURE 6. Presentation of NP147–155 in butabindide-treated cells. A, P815 cells adapted to grow in serum-free OPTI-MEM were treated overnight with 100 µM butabindide, infected with the indicated vac in the presence of the inhibitor, and used as targets in a 51Cr release assay for presentation of NP147–155. Untreated cells were used as controls. Lysates prepared from butabindide-treated or untreated P815 cells were subjected to AAF-AMC (B) and LLE-NA (C) activities as described in Materials and Methods.

As a final approach to examine specifically whether TPP II plays a key role in the pathway that is responsible for the generation of NP_147–155, a recombinant vac was generated expressing functional TPP II. If TPP II activity can enhance NP_147–155 generation in a proteasome-independent manner, then higher levels of this enzyme should compete for an Ag processing substrate and increase the efficiency of NP_147–155 presentation. Fig. 7A shows that increased AAF-AMC hydrolyzing activity in cell extracts was detected as early as 2 h postinfection with TPP II vac and reached a maximum between 4 and 8 h postinfection when TPP II activity was 2-fold higher than in control vac-infected cells. Because the significant endogenous TPP II-like activity in the normal L-K^d cells may obscure the effects of overexpression of TPP II, cells were treated overnight with AAF-cmk, washed, and infected with TPP II or control vac in the absence of inhibitor. Such treatment resulted in a 10-fold increase in AAF-AMC hydrolyzing activity compared with cells infected with a control vac (Fig. 7B). TPP II is a multimeric protease complex that may require proper assembly for normal function (26, 48). Superose 6 gel filtration chromatography revealed that the increase in AAF-AMC hydrolyzing activity detected under these conditions of TPP II vac infection corresponded to a single peak eluting just before the 26S proteasome (Figs. 7C and 6D) as reported previously (25, 26). This indicates that vac-expressed TPP II was not only functional but also formed proper multimeric complexes. The increase in activity in individual fractions from gel filtration was 5- to 10-fold under these conditions (data not shown) in good agreement with the whole cell extract data shown in Fig. 6, A and B. Note that proteasome function remains essentially unchanged under conditions of TPP II overexpression (Fig. 6C). Thus, using this overexpression approach a 10-fold increase in properly assembled functional TPP II was achieved.

View larger version (36K): [in this window] [in a new window]   FIGURE 7. Overexpression of TPP II. A, A time-dependent increase in AAF-AMC hydrolyzing activity was detected in crude cell extracts generated from cells infected with TPP II vac (dark bars) or a control vac (light bars). Lysates were generated at the indicated times from 106 cells infected with 5 pfu/cell of either vac. Crude cell lysates were assayed for the hydrolysis of AAF-AMC and fluorescence described in Materials and Methods. Background fluorescence of AAF-AMC alone is indicated by the bar on the lower left of each graph. B. The endogenous TPP II-like activity could be blocked with AAF-cmk pretreatment resulting in a 10-fold overexpression of AAF-AMC hydrolyzing activity. L-Kd cells were pretreated overnight with the indicated concentrations of AAF-AMC, washed 2 times in BSS/BSA and 1.75 x 106 cells infected with TPP II () or control vac () for 6 h. Cells were lysed and AAF-AMC hydrolyzing activity measured as in A. Overnight treatment with AAF-cmk at 50 µM did not alter total suc-LLVY-AMC hydrolyzing activity in crude cell extracts (data not shown). C and D, Cells were pretreated for 12 h with AAF-cmk, washed twice in BSS/BSA, and infected with 3 PFU/cell of the indicated vac for 9 h. Superose 6 gel filtration was performed on lysates and each fraction tested for proteasome activity (using suc-LLVY-AMC; C) or TPP II activity (using AAF-AMC; D). Open symbols indicate infection with control vac, and closed symbols indicate infection with TPP II vac. The suc-LLVY-AMC profiles in untreated cells infected with either TPP II or control virus were also similar (data not shown).

View larger version (30K): [in this window] [in a new window]   FIGURE 8. Overexpression of TPP II does not enhance epitope presentation. A and B, Conditions that allowed a 10-fold overexpression of TPP II activity using TPP II vac were used to assess presentation of NP50–57 (A) and NP147–155 (B). Normal L-Kd cells were pretreated overnight with 50 µM AAF-cmk, washed twice, and coinfected with 5 PFU/cell of the indicated Ag expressing vacs and 5 PFU/cell control vac (OVA vac) or TPP II vac. A series of HP-NP vacs were again used to limit Ag expression. No increase in presentation of either epitope is observed. In neither case is the presentation of epitopes from minigene constructs affected. C, Overexpressed TPP II does not restore presentation of NP147–155 from the A146P NP and does not alter presentation of NP147–155 from A146P NP in the presence of proteasome inhibitor (50 µM LLNL). The four bars indicate the E:T ratios 77:1, 26:1, 9:1, and 3:1.

One possible explanation for the results described above is that a protease other than the proteasome or TPP II is involved in the generation of NP_147–155. Indeed, several other cytosolic proteases have been implicated in Ag processing. These include at least two enzymes, PSA and BH, that have been reported to be inhibited by AAF-cmk (32, 36). In addition, TO and the IFN--inducible LA have been proposed to act as either productive or destructive postproteasomal trimming enzymes (33, 34, 35, 49). To test whether any of these proteases contributes to productive NP_147–155 generation, recombinant vacs expressing each of the four proteases were constructed. Overexpression by this approach resulted in a 5- to 10-fold increase in protease activity (data not shown). To discern even subtle changes in the efficiency of NP_147–155 production in the presence of higher activity of each of these proteases, two methods of limiting Ag presentation were used (Fig. 9). First, a HP recombinant (HP18) was used as described above to limit Ag expression (Fig. 9A). Second, BFA was used to limit presentation of NP_147–155 and NP_50–57. BFA limits egress from the Golgi to the cell surface and prevents the continued increase in cell surface peptide MHC complexes during CTL assays (14). Fig. 9 demonstrates that, even under limiting conditions, no substantial change in epitope presentation was observed, positively or negatively, as a result of overexpression of any of the five proteases.

View larger version (18K): [in this window] [in a new window]   FIGURE 9. Overexpression of four additional proteases does not augment epitope presentation even under limiting conditions. The coinfection approach was used to overexpress PSA, BH, TO, and LA (and TPP II again) and test the processing and presentation of NP50–57 and NP147–155. A, A standard 51Cr release assay using normal L-Kd cells was performed to test NP147–155 presentation from an HP-limited NP expression construct in the absence of additional protease expression or when each of the indicated enzymes was overexpressed. B and C, BFA-limited NP50–57 (B) or NP147–155 (C) processing and presentation was not enhanced by any of the overexpressed proteases. BFA (5 µg/ml final) was added at 150 min postinfection or not at all (NP bars), and presentation was assessed in a standard 51Cr release assay. Control indicates infection with vac expressing an irrelevant Ag. The three bars for each condition indicate the E:T ratios 33:1, 11:1, and 4:1.

Having determined that TPP II and other cytosolic proteases are unlikely to play a role in the generation of the proteasome-independent NP_147–155 epitope, we turned to a second possible explanation for this unusual presentation phenotype—that proteasome inhibitors do not completely inactivate the proteasome, but rather alter cleavage specificity in a manner that leads to greater NP_147–155 production. To investigate this, purified proteasome was incubated for 2 h with a 19 aa substrate containing the NP_147–155 epitope flanked by five additional NP residues on either side (NLNDATYQRTRALVRTGMD, epitope in bold) in the absence or presence of Lac. The digest was then separated by HPLC, and the peptide species were identified by mass spectrometry as described in Materials and Methods. Analyses revealed that Lac causes substantial reduction in activity at the previously described major cleavage site within the epitope (Fig. 10A). This is indicated by the nearly complete loss of the readily detectable N₁₄₂-R₁₅₂ product (NLNDATYQRTR) and commensurate preservation of the input peptide. More prolonged incubation (24 h) caused the generation of many species under both conditions (Fig. 10B), indicating that the proteasome is not incapacitated by Lac. Of note, the fragmentation patterns were clearly distinct, and this was also apparent on the HPLC tracings (data not shown). The large number of fragments and their frequent coelution precluded determination of relative amounts. Nevertheless, it is clear that Lac allows for the generation of many more species that contain the epitope (indicated by a thicker line in Fig. 10B). Indeed, in the no Lac sample, the complete epitope is present in only the input peptide while it is completely contained within several products extended at the N and/or C termini in the plus Lac digest (indicated by arrows in Fig. 10B). Three other aspects of the long-term digests are worth noting. First, addition of the inhibitor produces more species that are N-terminally extended, particularly at D₁₄₅ and A₁₄₆. Second, although addition of the inhibitor does not completely prevent cleavage at R, the activity is presumably much lower given the presence of many more species in which the R₁₅₂-T₁₅₃ bond is preserved. Finally, the minimal epitope itself is generated in the presence of Lac, but this peptide is within a relatively minor HPLC peak (data not shown). The strong bias toward extended versions of the epitope may explain the greater dependence on AAF-cmk-sensitive activity for presentation of NP_50–57 and NP_366–374 in adapted cells (Fig. 4). Taken together, these results indicate that Lac strongly reduces action at the major cleavage site within the epitope while modulating activity at secondary cleavage sites.

View larger version (15K): [in this window] [in a new window]   FIGURE 10. Cell-free proteasome digest of 19-mer peptide containing the NP147–155 epitope flanked by 5 aa from NP on either side reveals qualitative differences in substrate cleavage in the presence of Lac. A, The 19-mer peptide was digested with purified 20S proteasome in the absence (top panel) or presence of 20 µM Lac for 2 h. The digest was then separated by HPLC (tracings shown), and the indicated peptide species were determined by mass spectrometry. B, Prolonged (24 h) digestion of the 19-mer peptide with proteasome. A similar analysis was conducted, and the various products identified under both conditions are shown. Those products containing the NP147–155 are indicated with an arrow at the right. The major proteasome cleavage site between R152 and A153 is indicated by a dashed line.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

Our focus on TPP II was driven by the suggestion from several studies that TPP II can compensate for some proteasome functions. In cells chronically treated with the proteasome inhibitors Z-L₃-VS or Lac, TPP II activity is markedly up-regulated (25, 26), and inhibition of TPP II in these adapted cells, an innocuous treatment in normal cells, results in cell death (see above and Ref.25). TPP II is capable of preventing accumulation of polyubiquitinated proteins in the presence of acute proteasome inhibition, suggesting that the presence of TPP II can prevent the major block in protein degradation that is caused by reduced proteasome function (29). Several observations have also suggested that TPP II is capable of contributing to class I-restricted Ag processing. In Z-L₃-VS-adapted cells where proteasome is impaired but TPP II activity is substantially up-regulated, MHC I molecules continue to be properly assembled, indicating the availability of MHC I-binding peptides (25, 26, 29). Also, cell-free digests have demonstrated that TPP II can degrade substrates by both endo- and exoproteolytic cleavage and can generate peptide fragments that are the correct size for TAP transport and MHC I binding (7–27 aa; Ref.26). With respect to the generation of specific CTL epitopes, three observations could be interpreted as the participation of TPP II. First, Levy et al. provided evidence based on cell-free digests that TPP II (and PSA) could trim proteasomal degradation products to generate a precise CTL epitope, thus placing TPP II in a downstream role (32). Second, a recent study by Reits et al. (31) suggests that TPP II has a major role in handling proteasomal degradation products > 15 aa long and that the action of TPP II can be either endoproteolytic or N-terminal exoproteolytic. This model also places TPP II downstream of the proteasome but perhaps upstream of aminopeptidases involved in N-terminal trimming (e.g., ERAAP (52)). In a third study, RNAi was used to inhibit TPP II expression (30). Presentation of the HIV Nef_73–82 epitope was reduced in cells in which TPP II expression was blocked, and this was interpreted as evidence of a proteasome-independent/TPP II-dependent processing event. However, it is also possible that the required activity of TPP II for Nef_73–82 production occurs following initial proteasomal cleavage since the proteasome would still have been active under conditions of RNAi treatment.

In the present study, we demonstrate that AAF-cmk, a potent inhibitor of TPP II, but not the proteasome, significantly impairs the generation of NP_147–155 in normal cells and reduces processing and presentation of NP_147–155 and a second epitope (NP_50–57) to a lesser extent in Z-L₃-VS-adapted cells. While these results are suggestive of the involvement of TPP II, AAF-cmk has a rather broad specificity, and these results could indicate the involvement of other proteases. For a more direct examination of the role of TPP II as a proteasome-independent processing pathway, we used three approaches. First, we blocked TPP II expression using RNAi. In contrast to the study examining the presentation of the HIV Nef_73–82 CTL epitope (30), inhibiting TPP II expression using RNAi had no effect on NP_147–155 processing. Because the level of TPP II inhibition was not reported in the earlier study, it is hard to determine whether the discrepancy between ours and the previous study represents a difference in the level of TPP II inhibition, a difference in human vs mouse cells, or a differential dependency on TPP II activity for the Nef and NP epitopes. As a second approach to address the role of TPP II in NP_147–155 Ag processing, we overexpressed this enzyme and examined presentation of the two NP epitopes. Overexpressing components of the proteasome complex has been shown to enhance epitope presentation in other systems (53, 54, 55), indicating that changes in Ag processing efficiency can be discerned using this approach if the protease in question has a central role in epitope generation. However, substantial differences in levels of TPP II expression failed to alter epitope presentation. Inhibition of endogenous TPP II, a treatment that reduces NP_147–155 presentation, followed by 10-fold overexpression of TPP II activity failed to enhance NP_147–155 generation. Even when the synthesis and presentation of NP was limited, an approach that can reveal Ag processing patterns obscured by protein overexpression (15), no change in NP_50–57 or NP_147–155 was detected in the presence of increased levels of functional TPP II. Finally, butabindide, a more specific inhibitor of TPP II than AAF-cmk (31), had no detectable impact on NP_147–155 presentation, despite eliminating nearly all detectable TPP II activity. Taken together, these experiments suggest that any role TPP II might play in the generation of NP_147–155 is minimal and not critical.

Based on these results, we turned to the seemingly paradoxical possibility that the proteasome, even in the presence of proteasome inhibitors, might be required for NP_147–155 generation. Digestion of a synthetic 19-mer segment of NP containing NP_147–155 with purified proteasome has demonstrated the major cleavage site to be within the epitope (TYQRTRALV) (14), and this same cleavage is enhanced in the presence of the A146P mutation (14). Including proteasome inhibitors during the cell-free digests leads to an altered pattern of substrate cleavage that results in greatly reduced activity at the major cleavage site. In addition, prolonged digestion shows that cleavage at the precise N and C termini of NP_147–155 by the proteasome is not efficient, suggesting that postproteasomal proteases are required to generate the precise 9 aa peptide recognized by CTL. In contrast to the likely scenario in intact cells, substrates may reenter the proteasome in cell-free digests and be subject to multiple cycles of cleavage. Thus, the proportion of N-terminally extended species generated in intact cells may be underestimated by cell-free digestion. Notably, in the presence of a proteasome inhibitor, a number of epitope precursors were generated.

Although AAF-cmk has no effect on the generation of NP_50–57 under normal conditions, presentation appears to be partially reduced by this inhibitor under conditions of chronic proteasome impairment. The reduction is not as dramatic as for NP_147–155. Altogether these results suggest that the altered Ag processing in chronically treated cells is due not only to modulated proteasome but also a shift in the proteolytic profile of the cell to a state that depends more heavily on postproteasomal enzymes. The lack of survival of adapted cells in the presence of AAF-cmk observed by Glas et al. (25) may be due to the compensatory increase in TPP II, and perhaps other proteases, that act downstream of the proteasome. In such a scenario, postproteasomal proteases might play a critical role in cell metabolism as well as Ag processing since the proteasome, while still operable in proteasome-inhibitor adapted cells (29, 50), is probably less efficient than under normal conditions. Further work will be necessary to clarify these issues.

Although, in principle, modulated proteasome could account entirely for the processing of NP_147–155, the participation of a nonproteasomal activity in epitope production is a reasonable concept given the demonstrated contribution of other proteases to MHC I Ag processing (25, 26, 30, 32, 33, 34, 35, 36, 49, 52, 56). The majority of these proteases has been suggested to act downstream of the proteasome, in a trimming capacity. The demonstration of proteases such as leucine aminopeptidase, PSA, and BH as cytosolic postproteasomal trimming enzymes fits well with published data showing that, in many cases, proteasomal degradation generates N-terminally extended epitope precursors (57, 58). Of note, in addition to TPP II, AAF-cmk also inhibits the activity of PSA and BH (36). However, using a protease overexpression approach, increased levels of leucine aminopeptidase, PSA, BH, and TO do not appear to have a major impact on NP epitope production. In no case did we observe a significant change (either positive or negative) in the processing and presentation of either NP_147–155 or NP_50–57, even under limiting conditions. Thus, none of the five nonproteasomal proteases that has been associated with Ag processing appears to have a significant impact on the presentation of NP_50–57 and NP_147–155. It is possible that there is already sufficient activity of the relevant postproteasomal trimming enzyme available to act on a limited amount of NP_147–155 containing substrate generated by another rate-limiting step (e.g., proteasomal processing). In this situation, increased expression might not increase epitope production. We do note, however, that TO overexpression (achieved with a transfection system that is likely not as potent as the recombinant vac system we used) was found to inhibit substantially the presentation of the Ova_257–264 epitope (49), suggesting that overexpression is a valid strategy for evaluating the role of proteases in Ag processing. We speculate that our failure to observe similar destructive activity indicates that such effects are epitope specific. It is also possible that the action of postproteasomal processing enzymes may be redundant, in which case it would be difficult to discern the specific requirement of an individual protease. A third, intriguing possibility is that additional, as yet unidentified cytosolic, protease(s) may be involved in the processing of NP_147–155, a model that is accommodated by the broad specificity of AAF-cmk. Given our initial goal of finding potential substitutes for the proteasome, our analysis was confined to cytosolic proteases; however, ERAP1/ERAAP may also be an important postprotesomal peptide modifier, although we are not aware of reports demonstrating inhibition of ERAP1/ERAAP by AAF-cmk. Future experiments will be necessary to distinguish between these possibilities and to determine whether there is a novel AAF-cmk-sensitive protease in this pathway. It should be noted that our data do not eliminate the possibility that, in the generation of NP_147–155 and NP_50–57 (especially in adapted cells), another AAF-cmk-sensitive protease substitutes for the proteasome, but, for reasons elaborated above, we disfavor this notion.

The data presented in the current study support a model for the generation of epitopes such as NP_147–155 that are produced more efficiently in the presence of proteasome inhibitors in which initial, inefficient, proteasomal processing is followed by the action of postproteasomal enzymes that liberate precise epitopes from epitope-containing precursors. The effect of proteasome inhibitors in this model is to alter, but not completely ablate, proteasome activity preserving epitopes that would otherwise be destroyed. However, many important questions about this pathway remain unanswered. First, both acute and chronic proteasome inhibition leave the tryptic-like cleavage activity as the major residual proteasomal activity based on fluorogenic substrates. The destructive cleavage of NP_147–155 appears tryptic-like, but this Arg₁₅₂-Ala₁₅₃ cleavage is reduced rather than accentuated in the presence of Lac. Because allosteric effects of inhibitors and substrates may influence the specificity of proteasomal cleavage (4), it will be important to determine the specificity of residual proteasome activity on protein substrates in the presence of both acute and chronic proteasome inhibition. The three proteasome inhibitors used in this study, LLnL, Lac, and ZL3VS, all accentuate NP_147–155 presentation. This suggests that, if an altered proteasome is responsible for NP_147–155 generation in the presence of inhibitors, then LLnL, Lac, and ZL3VS induce similar functional changes in the proteasome. Indeed, including LLnL or Lac during CTL assays using the ZL₃VS-adapted cells did not substantially change presentation or NP_147–155 (data not shown). Given the similar effects on proteasome function and increase in presentation of NP_147–155 in normal cells, this result is perhaps not surprising. It will be important to develop additional proteasome inhibitors that can target different activities of the proteasome, including those that may be modulated by short-term or chronic treatment with LLnL, Lac, or ZL₃VS. Second, the majority of the nonproteasomal proteases implicated in MHC I Ag processing have N-terminal trimming activity, but C-terminally extended precursors of NP_147–155 are also likely to be generated based on cell-free digests. Although some data suggests the presence of C-terminal trimming activities are not as abundant or as active as N-terminal processing enzymes, the possible involvement of cytosolic C-terminal trimming proteases is currently being assessed. Lastly, what are the potential implications of these results for protective immunity? Many epitopes have now been identified that are produced or presented more efficiently when proteasome activity is impaired or altered (16, 17, 18, 19, 20, 21, 22). During chronic infections or cancer, it may be beneficial to alter the spectrum or level of epitopes produced in vivo to boost T cell recognition or to increase the potential targets for T cell recognition. The HIV protease inhibitor ritonavir has been reported to impair proteasome activity (59). It may be interesting to determine whether this compound or other proteasome inhibitors that can be used in vivo alter CTL activity toward epitopes such as NP_147–155 in animal models. A more complete understanding of this degradation pathway may lead to approaches that selectively modify epitope presentation in vivo.

	Acknowledgments

 
We thank Dr. Birgitta Tomkinson (University of Uppsala, Uppsala, Sweden) for the cDNA encoding murine TPP II, Susan Renn and Dr. Paul Taghert (Washington University School of Medicine, St. Louis, MO) for supplying purified drosophila TPP II and butabindide, Dr. George DeMartino (University of Texas Southwestern Medical Center, Dallas, TX) for supplying purified bovine 20S proteasome, Drs. Mathew Bogyo (University of San Francisco, San Francisco, CA) and Hidde Ploegh (Harvard University, Boston, MA) for providing Z-L₃-VS, and Dr. Garrett Dubois (Thomas Jefferson University, Philadelphia, PA) for assistance and expertise with gel filtration experiments. We thank Amy Harth and Bozena Zietara for providing outstanding technical assistance and Andrew Beckwith and Drs. Deepa Rajagopal and Ournia Tatsis for critically reading the manuscript.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The authors have no financial conflict of interest.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by American Cancer Society Grant RP6-98-036-01-C1M (to L.C.E.) and National Institutes of Health Grant AI39501 (to L.C.E.). E.J.W. was supported by National Institutes of Health Training Grant AIO7492 during this work.

² Current address: Immunology Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104

³ Address correspondence and reprint requests to Dr. Laurence C. Eisenlohr, Thomas Jefferson University, BLSB, Room 730, 233 South 10th Street, Philadelphia, PA, 19107. E-mail address: Lawrence.Eisenlohr{at}mail.jci.tju.edu

⁴ Abbreviations used in this paper: ER, endoplasmic reticulum; TAP, transporter associated with Ag presentation; MHC I, MHC class I; LLnL, N-Ac-Leu-Leu-norleucinal; Lac, lactacystin; NP, nucleoprotein; A146P, influenza NP with aa 146 mutated from alanine to proline; TPP II, tripeptidyl peptidase II; Z-L₃-VS, carbobenzoxy-Leu-Leu-Leu-vinyl sulfone; TO, thimet oligopeptidase; BH, bleomycin hydrolase; PSA, puromycin-sensitive aminopeptidase; HP, hairpin; vac, vaccinia virus; AAF-cmk, Ala-Ala-Phe-chloromethyl ketone; suc-LLVY-AMC, N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin; AAF-AMC, Ala-Ala-Phe-7-amido-4-methylcoumarin; RNAi, RNA interference; BFA, brefeldin A; BSS, buffered salt solution.

Received for publication July 1, 2004. Accepted for publication November 16, 2005.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Niedermann, G., E. Geier, M. Lucchiari-Hartz, N. Hitziger, A. Ramsperger, K. Eichmann. 1999. The specificity of proteasomes: impact on MHC class I processing and presentation of antigens. Immunol. Rev. 172: 29-48. [Medline]
2. Rock, K. L., A. L. Goldberg. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17: 739-779. [Medline]
3. Stoltze, L., A. K. Nussbaum, A. Sijts, N. P. Emmerich, P. M. Kloetzel, H. Schild. 2000. The function of the proteasome system in MHC class I antigen processing. Immunol. Today 21: 317-319. [Medline]
4. Kisselev, A. F., T. N. Akopian, V. Castillo, A. L. Goldberg. 1999. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell 4: 395-402. [Medline]
5. Saveanu, L., D. Fruci, P. van Endert. 2002. Beyond the proteasome: trimming, degradation and generation of MHC class I ligands by auxiliary proteases. Mol. Immunol. 39: 203-215. [Medline]
6. Del-Val, M., D. Lopez. 2002. Multiple proteases process viral antigens for presentation by MHC class I molecules to CD8⁺ T lymphocytes. Mol. Immunol. 39: 235-247. [Medline]
7. Craiu, A., T. Akopian, A. Goldberg, K. Rock. 1997. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc. Natl. Acad. Sci. USA 94: 10850-10855. [Abstract/Free Full Text]
8. Lopez, D., M. Del Val. 1997. Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. J. Immunol. 159: 5769-5772. [Abstract]
9. Mo, X. Y., P. Cascio, K. Lemerise, A. L. Goldberg, K. Rock. 1999. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol. 163: 5851-5859. [Abstract/Free Full Text]
10. Serwold, T., S. Gaw, N. Shastri. 2001. ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat. Immunol. 2: 644-651. [Medline]
11. Saric, T., S. C. Chang, A. Hattori, I. A. York, S. Markant, K. L. Rock, M. Tsujimoto, A. L. Goldberg. 2002. An IFN--induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3: 1169-1176. [Medline]
12. York, I. A., S. C. Chang, T. Saric, J. A. Keys, J. M. Favreau, A. L. Goldberg, K. L. Rock. 2002. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8–9 residues. Nat. Immunol. 3: 1177-1184. [Medline]
13. Saveanu, L., O. Carroll, V. Lindo, M. Del Val, D. Lopez, Y. Lepelletier, F. Greer, L. Schomburg, D. Fruci, G. Niedermann, P. M. van Endert. 2005. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat. Immunol. 6: 689-697. [Medline]
14. Yellen-Shaw, A., J. Wherry, G. C. Dubois, L. Eisenlohr. 1997. Point mutation flanking a CTL epitope ablates recognition of a full-length viral protein. J. Immunol. 158: 3227-3234. [Abstract]
15. Golovina, T. N., E. J. Wherry, T. N. Bullock, L. C. Eisenlohr. 2002. Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum. J. Immunol. 168: 2667-2675. [Abstract/Free Full Text]
16. Vinitsky, A., L. Anton, H. Snyder, M. Orlowski, J. Bennink, J. Yewdell. 1997. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors. J. Immunol. 159: 554-564. [Abstract]
17. Luckey, C. J., G. M. King, J. A. Marto, S. Venketeswaran, B. F. Maier, V. L. Crotzer, T. A. Colella, J. Shabanowitz, D. F. Hunt, V. H. Engelhard. 1998. Proteasome can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J. Immunol. 161: 112-121. [Abstract/Free Full Text]
18. Anton, L., H. Snyder, J. Bennink, A. Vinitsky, M. Orlowski, A. Porgador, J. Yewdell. 1998. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol. 160: 4859-4868. [Abstract/Free Full Text]
19. Valmori, D., U. Gileadi, C. Servis, P. R. Dunbar, J. C. Cerottini, P. Romero, V. Cerundolo, F. Levy. 1999. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189: 895-906. [Abstract/Free Full Text]
20. Sewell, A. K., D. A. Price, H. Teisserenc, B. L. Booth, Jr, U. Gileadi, F. M. Flavin, J. Trowsdale, R. E. Phillips, V. Cerundolo. 1999. IFN- exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. J. Immunol. 162: 7075-7079. [Abstract/Free Full Text]
21. Luckey, C. J., J. A. Marto, M. Partridge, E. Hall, F. M. White, J. D. Lippolis, J. Shabanowitz, D. F. Hunt, V. H. Engelhard. 2001. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J. Immunol. 167: 1212-1221. [Abstract/Free Full Text]
22. Choppin, J., W. Cohen, A. Bianco, J. P. Briand, F. Connan, M. Dalod, J. G. Guillet. 2001. Characteristics of HIV-1 Nef regions containing multiple CD8⁺ T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. J. Immunol. 166: 6164-6169. [Abstract/Free Full Text]
23. Dick, T. P., A. K. Nussbaum, M. Deeg, W. Heinemeyer, M. Groll, M. Schirle, W. Keilholz, S. Stevanovic, D. H. Wolf, R. Huber, et al 1998. Contribution of proteasomal -subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem. 273: 25637-25646. [Abstract/Free Full Text]
24. Niedermann, G., S. Butz, H. Ihlenfeldt, R. Grimm, M. Lucchiari, H. Hoschutzky, G. Jung, B. Maier, K. Eichmann. 1995. Contribution of proteosome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2: 289-299. [Medline]
25. Glas, R., M. Bogyo, J. McMaster, M. Gaczynska, H. Ploegh. 1998. A proteolytic system that compensates for loss of proteasome function. Nature 392: 618-622. [Medline]
26. Geier, E., G. Pfeifer, M. Wilm, M. Lucchiari-Hartz, W. Baumeister, K. Eichmann, G. Niedermann. 1999. A giant protease with potential to substitute for some functions of the proteasome. Science 283: 978-981. [Abstract/Free Full Text]
27. Balow, R. M., U. Ragnarsson, O. Zetterqvist. 1983. Tripeptidyl aminopeptidase in the extralysosomal fraction of rat liver. J. Biol. Chem. 258: 11622-11628. [Abstract/Free Full Text]
28. Balow, R., B. Tomkinson, U. Ragnarsson, O. Zetterqvist. 1986. Purification, substrate specificity, and classification of tripeptidyl peptidase II. J. Biol. Chem. 261: 2409-2417. [Abstract/Free Full Text]
29. Wang, E. W., B. M. Kessler, A. Borodovsky, B. F. Cravatt, M. Bogyo, H. L. Ploegh, R. Glas. 2000. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc. Natl. Acad. Sci. USA 97: 9990-9995. [Abstract/Free Full Text]
30. Seifert, U., C. Maranon, A. Shmueli, J. F. Desoutter, L. Wesoloski, K. Janek, P. Henklein, S. Diescher, M. Andrieu, H. de la Salle, et al 2003. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4: 375-379. [Medline]
31. Reits, E., J. Neijssen, C. Herberts, W. Benckhuijsen, L. Janssen, J. W. Drijfhout, J. Neefjes. 2004. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20: 495-506. [Medline]
32. Levy, F., L. Burri, S. Morel, A. L. Peitrequin, N. Levy, A. Bachi, U. Hellman, B. J. Van den Eynde, C. Servis. 2002. The final N-terminal trimming of a subaminoterminal proline-containing HLA class I-restricted antigenic peptide in the cytosol is mediated by two peptidases. J. Immunol. 169: 4161-4171. [Abstract/Free Full Text]
33. Beninga, J., K. L. Rock, A. L. Goldberg. 1998. Interferon can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J. Biol. Chem. 273: 18734-18742. [Abstract/Free Full Text]
34. Portaro, F. C., M. D. Gomes, A. Cabrera, B. L. Fernandes, C. L. Silva, E. S. Ferro, L. Juliano, A. C. de Camargo. 1999. Thimet oligopeptidase and the stability of MHC class I epitopes in macrophage cytosol. Biochem. Biophys. Res. Commun. 255: 596-601. [Medline]
35. Silva, C. L., F. C. Portaro, V. L. Bonato, A. C. de Camargo, E. S. Ferro. 1999. Thimet oligopeptidase (EC 3.4.24.15), a novel protein on the route of MHC class I antigen presentation. Biochem. Biophys. Res. Commun. 255: 591-595. [Medline]
36. Stoltze, L., M. Schirle, G. Schwarz, C. Schroter, M. W. Thompson, L. B. Hersh, H. Kalbacher, S. Stevanovic, H. G. Rammensee, H. Schild. 2000. Two new proteases in the MHC class I processing pathway. Nat. Immunol. 1: 413-418. [Medline]
37. Wherry, E. J., K. A. Puorro, A. Porgador, L. C. Eisenlohr. 1999. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163: 3735-3745. [Abstract/Free Full Text]
38. Wherry, E. J., D. Rajagopal, L. C. Eisenlohr. 2001. Use of vaccinia virus expression vectors to investigate antigen processing and presentation. Methods Mol. Biol. 156: 89-109. [Medline]
39. Bogyo, M., J. McMaster, M. Gaczynska, D. Tortorella, A. Goldberg, H. Ploegh. 1997. Covalent modification of the active site threonine of proteasomal subunits and the Escherichia coli homolog HsIV by a new class of inhibitors. Proc. Natl. Acad. Sci. USA 94: 6629-6634. [Abstract/Free Full Text]
40. Bosserhoff, A., J. Wallach, R. W. Frank. 1989. Micropreparative separation of peptides derived from sodium dodecyl sulphate-solubilized proteins. J. Chromatogr. 473: 71-77. [Medline]
41. Draenert, R., S. Le Gall, K. J. Pfafferott, A. J. Leslie, P. Chetty, C. Brander, E. C. Holmes, S. C. Chang, M. E. Feeney, M. M. Addo, et al 2004. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J. Exp. Med. 199: 905-915. [Abstract/Free Full Text]
42. Tomkinson, B., L. Grehn, B. Fransson, O. Zetterqvist. 1994. Use of a dehydroalanine-containing peptide as an efficient inhibitor of tripeptidyl peptidase II. Arch. Biochem. Biophys. 314: 276-279. [Medline]
43. Wherry, E. J., M. J. McElhaugh, L. C. Eisenlohr. 2002. Generation of CD8⁺ T cell memory in response to low, high, and excessive levels of epitope. J. Immunol. 168: 4455-4461. [Abstract/Free Full Text]
44. Bullock, T. N. J., L. Eisenlohr. 1996. Ribosomal scanning past the primary initiation codon as a mechanism for expression of CTL epitopes encoded in alternative reading frames. J. Exp. Med. 184: 1319-1329. [Abstract/Free Full Text]
45. Yellen-Shaw, A., C. Laughlin, R. Metrione, L. Eisenlohr. 1997. Murine transporter associated with antigen presentation (TAP) preferences influence class I-restricted T cell responses. J. Exp. Med. 186: 1655-1662. [Abstract/Free Full Text]
46. Rock, K., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, A. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771. [Medline]
47. Warburton, M. J., F. Bernardini. 2002. Tripeptidyl peptidase-I is essential for the degradation of sulphated cholecystokinin-8 (CCK-8S) by mouse brain lysosomes. Neurosci. Lett. 331: 99-102. [Medline]
48. Macpherson, E., B. Tomkinson, R. M. Balow, S. Hoglund, O. Zetterqvist. 1987. Supramolecular structure of tripeptidyl peptidase II from human erythrocytes as studied by electron microscopy, and its correlation to enzyme activity. Biochem. J. 248: 259-263. [Medline]
49. York, I. A., A. X. Mo, K. Lemerise, W. Zeng, Y. Shen, C. R. Abraham, T. Saric, A. L. Goldberg, K. L. Rock. 2003. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18: 429-440. [Medline]
50. Princiotta, M. F., U. Schubert, W. Chen, J. R. Bennink, J. Myung, C. M. Crews, J. W. Yewdell. 2001. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc. Natl. Acad. Sci. USA 98: 513-518. [Abstract/Free Full Text]
51. Gaczynska, M., P. A. Osmulski. 2005. Small-molecule inhibitors of proteasome activity. Methods Mol. Biol. 301: 3-22. [Medline]
52. Serwold, T., F. Gonzalez, J. Kim, R. Jacob, N. Shastri. 2002. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419: 480-483. [Medline]
53. Groettrup, M., A. Soza, M. Eggers, L. Kuehn, T. Dick, H. Schild, H. Rammensee, U. Koszinowski, P. Kloetzel. 1996. A role for the proteasome regulator PA28- in antigen presentation. Nature 381: 166-168. [Medline]
54. Schultz, E. S., J. Chapiro, C. Lurquin, S. Claverol, O. Burlet-Schiltz, G. Warnier, V. Russo, S. Morel, F. Levy, T. Boon, et al 2002. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J. Exp. Med. 195: 391-399. [Abstract/Free Full Text]
55. van Hall, T., A. Sijts, M. Camps, R. Offringa, C. Melief, P. M. Kloetzel, F. Ossendorp. 2000. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med. 192: 483-494. [Abstract/Free Full Text]
56. Serwold, T., S. Gaw, N. Shastri. 2001. ER aminopeptidases generate a unique pool of peptides for MHC class I molecules. Nat. Immunol. 2: 644-651. [Medline]
57. Kisselev, A. F., T. N. Akopian, A. L. Goldberg. 1998. Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. J. Biol. Chem. 273: 1982-1989. [Abstract/Free Full Text]
58. Kisselev, A. F., T. N. Akopian, K. M. Woo, A. L. Goldberg. 1999. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes: implications for understanding the degradative mechanism and antigen presentation. J. Biol. Chem. 274: 3363-3371. [Abstract/Free Full Text]
59. Andre, P., M. Groettrup, P. Klenerman, R. de Giuli, B. L. Booth, Jr, V. Cerundolo, M. Bonneville, F. Jotereau, R. M. Zinkernagel, V. Lotteau. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA 95: 13120-13124. [Abstract/Free Full Text]

Related articles in The JI:

IN THIS ISSUE

The JI 2006 176: 2051-2052. [Full Text]  

This article has been cited by other articles:

				M. Kawahara, I. A. York, A. Hearn, D. Farfan, and K. L. Rock Analysis of the Role of Tripeptidyl Peptidase II in MHC Class I Antigen Presentation In Vivo J. Immunol., November 15, 2009; 183(10): 6069 - 6077. [Abstract] [Full Text] [PDF]

				J. Diekmann, E. Adamopoulou, O. Beck, G. Rauser, S. Lurati, S. Tenzer, H. Einsele, H.-G. Rammensee, H. Schild, and M. S. Topp Processing of Two Latent Membrane Protein 1 MHC Class I Epitopes Requires Tripeptidyl Peptidase II Involvement J. Immunol., August 1, 2009; 183(3): 1587 - 1597. [Abstract] [Full Text] [PDF]

				C. Smith, N. Wakisaka, T. Crough, J. Peet, T. Yoshizaki, L. Beagley, and R. Khanna Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation Blood, June 11, 2009; 113(24): 6148 - 6152. [Abstract] [Full Text] [PDF]

				H. Barth, E. K. Schnober, C. Neumann-Haefelin, C. Thumann, M. B. Zeisel, H. M. Diepolder, Z. Hu, T. J. Liang, H. E. Blum, R. Thimme, et al. Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells J. Virol., April 1, 2008; 82(7): 3466 - 3479. [Abstract] [Full Text] [PDF]

				E. Firat, J. Huai, L. Saveanu, S. Gaedicke, P. Aichele, K. Eichmann, P. van Endert, and G. Niedermann Analysis of Direct and Cross-Presentation of Antigens in TPPII Knockout Mice1 J. Immunol., December 15, 2007; 179(12): 8137 - 8145. [Abstract] [Full Text] [PDF]

				C. F. Towne, I. A. York, L. B. Watkin, J. S. Lazo, and K. L. Rock Analysis of the Role of Bleomycin Hydrolase in Antigen Presentation and the Generation of CD8 T Cell Responses J. Immunol., June 1, 2007; 178(11): 6923 - 6930. [Abstract] [Full Text] [PDF]

				S. Guil, M. Rodriguez-Castro, F. Aguilar, E. M. Villasevil, L. C. Anton, and M. Del Val Need for Tripeptidyl-peptidase II in Major Histocompatibility Complex Class I Viral Antigen Processing when Proteasomes are Detrimental J. Biol. Chem., December 29, 2006; 281(52): 39925 - 39934. [Abstract] [Full Text] [PDF]

				M. L. Altrich-VanLith, M. Ostankovitch, J. M. Polefrone, C. A. Mosse, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard Processing of a Class I-Restricted Epitope from Tyrosinase Requires Peptide N-Glycanase and the Cooperative Action of Endoplasmic Reticulum Aminopeptidase 1 and Cytosolic Proteases J. Immunol., October 15, 2006; 177(8): 5440 - 5450. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Related articles in The JI Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wherry, E. J. Articles by Eisenlohr, L. C. Search for Related Content PubMed PubMed Citation Articles by Wherry, E. J. Articles by Eisenlohr, L. C. Pubmed/NCBI databases Substance via MeSH